Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 1
2007 1
2009 1
2010 1
2014 2
2015 1
2017 1
2018 5
2019 4
2021 2
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Pancreatic cancer, radiomics and artificial intelligence.
Marti-Bonmati L, Cerdá-Alberich L, Pérez-Girbés A, Díaz Beveridge R, Montalvá Orón E, Pérez Rojas J, Alberich-Bayarri A. Marti-Bonmati L, et al. Among authors: diaz beveridge r. Br J Radiol. 2022 Sep 1;95(1137):20220072. doi: 10.1259/bjr.20220072. Epub 2022 Jun 28. Br J Radiol. 2022. PMID: 35687700 Free PMC article. Review.
Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A.
Martin-Broto J, Martinez-Garcia J, Moura DS, Redondo A, Gutierrez A, Lopez-Pousa A, Martinez-Trufero J, Sevilla I, Diaz-Beveridge R, Solis-Hernandez MP, Carnero A, Perez M, Marcilla D, Garcia-Foncillas J, Romero P, Fernandez-Jara J, Lopez-Lopez D, Arribas I, Hindi N. Martin-Broto J, et al. Among authors: diaz beveridge r. Signal Transduct Target Ther. 2023 Oct 25;8(1):405. doi: 10.1038/s41392-023-01661-8. Signal Transduct Target Ther. 2023. PMID: 37875500 Free PMC article. Clinical Trial.
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gröschel S, Hatcher H, Duffaud F, Herráez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, Götze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Gounder MM, et al. Among authors: beveridge rd. J Clin Oncol. 2022 Aug 1;40(22):2479-2490. doi: 10.1200/JCO.21.01829. Epub 2022 Apr 8. J Clin Oncol. 2022. PMID: 35394800 Free PMC article. Clinical Trial.
Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort study.
Ochenduszko S, García Sanchez J, Fita MJJ, González-Barrallo I, Herrero Colomina J, Mujika K, Beveridge RD, Martínez SR, Lafuente BS, Tomas AC, Jaime AB, Cerezuela Fuentes P, Fra PL, Peeters AG, Meana García JA, García MAA, Altozano JP, Cancela M, Puchades AM, Roca FF, Maiques IM. Ochenduszko S, et al. Among authors: beveridge rd. Pigment Cell Melanoma Res. 2023 Sep;36(5):388-398. doi: 10.1111/pcmr.13093. Epub 2023 May 27. Pigment Cell Melanoma Res. 2023. PMID: 37243929
A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors.
Martin-Broto J, Redondo A, Moura DS, Valverde C, Morales JM, Lopez-Pousa A, Martinez-Trufero J, Gutierrez A, Díaz-Beveridge R, Luna P, Martinez-Marin V, Marcilla D, Arribas I, Ledesma P, Lopez-Martin JA, Di Lernia D, Zamora J, Hindi N. Martin-Broto J, et al. Among authors: diaz beveridge r. Nat Commun. 2022 Oct 21;13(1):6278. doi: 10.1038/s41467-022-33975-6. Nat Commun. 2022. PMID: 36271011 Free PMC article. Clinical Trial.
Identification Of Actionable Genetic Targets In Primary Cardiac Sarcomas.
Salvador-Coloma C, Saigí M, Díaz-Beveridge R, Penín RM, Pané-Foix M, Mayordomo E, Melián M, Schuler M, García Del Muro X, Font de Mora J. Salvador-Coloma C, et al. Among authors: diaz beveridge r. Onco Targets Ther. 2019 Nov 7;12:9265-9275. doi: 10.2147/OTT.S214319. eCollection 2019. Onco Targets Ther. 2019. PMID: 31807008 Free PMC article.
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.
Gonzalez-Cao M, Mayo de Las Casas C, Oramas J, Berciano-Guerrero MA, de la Cruz L, Cerezuela P, Arance A, Muñoz-Couselo E, Espinosa E, Puertolas T, Diaz Beveridge R, Ochenduszko S, Villanueva MJ, Basterretxea L, Bellido L, Rodriguez D, Campos B, Montagut C, Drozdowskyj A, Molina MA, Lopez-Martin JA, Berrocal A. Gonzalez-Cao M, et al. Among authors: diaz beveridge r. Nat Commun. 2021 Dec 1;12(1):7008. doi: 10.1038/s41467-021-26572-6. Nat Commun. 2021. PMID: 34853302 Free PMC article. Clinical Trial.
Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
Serrano C, García-Del-Muro X, Valverde C, Sebio A, Durán J, Manzano A, Pajares I, Hindi N, Landolfi S, Jiménez L, Rubió-Casadevall J, Estival A, Lavernia J, Safont MJ, Pericay C, Díaz-Beveridge R, Martínez-Marín V, Vicente-Baz D, Vivancos A, Hernández-Losa J, Arribas J, Carles J. Serrano C, et al. Among authors: diaz beveridge r. Oncologist. 2019 May;24(5):680-687. doi: 10.1634/theoncologist.2018-0032. Epub 2018 Aug 20. Oncologist. 2019. PMID: 30126859 Free PMC article.
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study.
Martínez-Trufero J, De Sande-González LM, Luna P, Martin-Broto J, Álvarez R, Marquina G, Diaz-Beveridge R, Poveda A, Cano JM, Cruz-Jurado J, López Pousa A, Vaz Salgado MA, Valverde-Morales CM, Sevilla I, Martínez-García J, Rubio-Casadevall J, De Juan A, Carrasco JA, Moura DS, Gurruchaga-Sotes I, Gutiérrez A. Martínez-Trufero J, et al. Among authors: diaz beveridge r. Cancers (Basel). 2021 Feb 14;13(4):792. doi: 10.3390/cancers13040792. Cancers (Basel). 2021. PMID: 33672857 Free PMC article.
23 results